2017-05-12Zeitschriftenartikel
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
Osman, Mohamed; Mistry, Anoop; Keding, Ada; Gabe, Rhian; Cook, Elizabeth; Forrester, Sarah; Wiggins, Rebecca; Marco, Stefania Di; Colloca, Stefano; Siani, Loredana; Cortese, Riccardo; Smith, Deborah F.; Aebischer, Toni; Kaye, Paul M.
Background: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin ...